Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples